Now that three of the world's biggest drug developers--J&J ($JNJ), Pfizer ($PFE) and Eli Lilly ($LLY)--have failed to demonstrate the efficacy of their leading Alzheimer's drugs among afflicted patients in Phase III, investigators have started off on a lengthy journey to see if one of the therapies in the pipeline can save people before they succumb to this memory-wasting ailment.
No comments:
Post a Comment